SuperworthPliant Therapeutics EPS PLRX
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$1.49
- Latest quarter, Q2 FY26
- −$0.36
- Fiscal year 2025
- −$2.44
Pliant Therapeutics' earnings per share was −$1.49 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.36.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.44 | n/a |
| FY2024 | −$3.47 | n/a |
| FY2023 | −$2.76 | n/a |
| FY2022 | −$2.97 | n/a |
| FY2021 | −$2.71 | n/a |
| FY2020 | −$2.40 | n/a |
| FY2019 | −$8.10 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.36 | n/a | −$1.49 | |
| Q1 FY26 | −$0.32 | n/a | −$1.84 | |
| Q4 FY25 | −$0.38 | n/a | −$2.44 | |
| Q3 FY25 | −$0.43 | n/a | −$2.88 | |
| Q2 FY25 | −$0.71 | n/a | −$3.40 | |
| Q1 FY25 | −$0.92 | n/a | −$3.61 | |
| Q4 FY24 | −$0.82 | n/a | −$3.47 | |
| Q3 FY24 | −$0.95 | n/a | −$3.34 | |
| Q2 FY24 | −$0.92 | n/a | −$3.09 | |
| Q1 FY24 | −$0.78 | n/a | −$2.87 | |
| Q4 FY23 | −$0.69 | n/a | −$2.76 | |
| Q3 FY23 | −$0.70 | n/a | −$2.79 |
Against its peers
Companies in Drug Manufacturers - General nearest Pliant Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PLRXPliant Therapeutics | −$1.49 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Pliant Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.